Cymabay Therapeutics Inc Stock
Your prediction
Cymabay Therapeutics Inc Stock
Pros and Cons of Cymabay Therapeutics Inc in the next few years
Pros
Cons
Performance of Cymabay Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cymabay Therapeutics Inc | - | - | - | - | - | - | - |
| Ardelyx Inc. | -4.590% | -3.853% | 15.454% | 108.097% | 19.170% | 20.842% | - |
| Evolus Inc | -5.830% | 2.564% | 13.208% | 34.078% | 32.597% | 61.074% | - |
| Salarius Pharmaceuticals Inc. | 5.580% | 3.141% | -10.860% | -67.167% | -29.009% | -98.470% | -99.993% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Assessing the financial standing of CymaBay, a frontrunner in the Biotechnology & Medical Research industry, the company portrays a mixed bag of circumstances. In one vein, its financial posture wrestles with certain impediments, while, on the other hand, it arms itself with potential growth drivers.
Analysis of financial ratios and its balance sheet unfolds a few favorable facets.
On the flip side, a host of challenges warrants immediate attention.
Comments
News
3 Dividend Stocks to Buy Hand Over Fist in March
Get paid to own a stock whether it moves higher or lower. What a concept! And it's one that any investor who buys dividend stocks can enjoy. Three Motley Fool contributors believe they've identified
Analysts see over 50% gains in these 2 mid-cap biotech stocks
2024 is shaping up to be a pivotal year for the biotechnology industry.
In recent years, emergency Covid vaccines have ushered in several groundbreaking innovations that have changed the way
